Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45887 | 0.94 | GLP1R (0.57) | GLP1RALBTLR2NOD1SIRT2 | |
| SCHEMBL13347257 | 0.91 | TLR2 (0.56) | GLP1RTLR2SIRT5CHRNA1CHRNG | |
| SCHEMBL12680258 | 0.91 | TLR2 (0.56) | GLP1RTLR2SIRT5CHRNA1CHRNG | |
| SCHEMBL13371966 | 0.89 | GLP1R (0.48) | GLP1RALBTLR2NOD1SIRT5 | |
| SCHEMBL14902999 | 0.89 | GLP1R (0.46) | GLP1RALBTLR2NOD1SIRT2 | |
| SCHEMBL16525843 | 0.87 | GLP1R (0.56) | GLP1RALBTLR2NOD1SIRT2 | |
| SCHEMBL45885 | 0.87 | GLP1R (0.56) | GLP1RALBTLR2NOD1SIRT2 | |
| SCHEMBL24601556 | 0.86 | GLP1R (0.52) | GLP1RALBTLR2NOD1SIRT2 | |
| SCHEMBL27143006 | 0.85 | GLP1R (0.57) | GLP1RALBNOD1CASP2 | |
| SCHEMBL26346478 | 0.84 | GLP1R (0.60) | GLP1RTLR2NOD1CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109619-A1 | PEPTIDE-BASED INHIBITOR OF INTERLEUKIN-10 OR INTERFERON-GAMMA SIGNALING | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109619-A1 | PEPTIDE-BASED INHIBITOR OF INTERLEUKIN-10 OR INTERFERON-GAMMA SIGNALING | IFNG, IFNAR1, CXCL10 | GLP1R 279/4885ALB 3280/4885TLR2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.